Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study

Shou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, Chung-Feng Huang, Chi-Yi Chen, Chao-Hung Hung, Chien-Hung Chen, Chi-Ming Tai, Pin-Nan Cheng, Hsing-Tao Kuo, Kuo-Chih Tseng, Lein-Ray Mo, Ching-Chu Lo, Yi-Hsiang Huang, Han-Chieh Lin, Pei-Lun Lee, Ming-Jong Bair, Te-Sheng Chang, Chun-Yen Lin, Szu-Jen Wang, Tsai-Yuan Hsieh, Tzeng-Hue Yang, Cheng-Yuan Peng, Chi-Chieh Yang, Lee-Won Chong, Chien-Wei Huang, Chih-Wen Lin, Cheng-Hsin Chu, Ming-Chang Tsai, Jia-Horng Kao, Chun-Jen Liu, Wan-Long Chuang, Teng-Yu Lee, Ming-Lung Yu, on behalf of TACR investigators

Clin Mol Hepatol. 2025;31(3):899-913. Published online February 5, 2025

DOI: https://doi.org/10.3350/cmh.2024.1015

View: 2366 Download: 153

Correspondence

Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”

Tom Ryu, Young Chang, Seung Up Kim, Jae Young Jang

Clin Mol Hepatol. 2025;31(2):e203-e205. Published online February 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0179

View: 733 Download: 19 Web of Science: 1 Crossref: 1

Original Article

Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C

Tom Ryu, Young Chang, Soung Won Jeong, Jeong-Ju Yoo, Sae Hwan Lee, Sang Gyune Kim, Young Seok Kim, Hong Soo Kim, Seung Up Kim, Jae Young Jang

Clin Mol Hepatol. 2025;31(2):548-562. Published online January 9, 2025

DOI: https://doi.org/10.3350/cmh.2024.0904

View: 1724 Download: 119 Web of Science: 4 Crossref: 1

Review

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy

Chung-Feng Huang, Ming-Lung Yu

Clin Mol Hepatol. 2020;26(3):251-260. Published online March 19, 2020

DOI: https://doi.org/10.3350/cmh.2020.0018

View: 16239 Download: 396 Web of Science: 46 Crossref: 48

Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure

Tommaso Lorenzo Parigi, Maria Corina Plaz Torres, Alessio Aghemo

Clin Mol Hepatol. 2019;25(4):360-365. Published online May 2, 2019

DOI: https://doi.org/10.3350/cmh.2019.0022

View: 6720 Download: 247 Web of Science: 10 Crossref: 12

Discussion on critical points for a tailored therapy to cure hepatitis C virus infection

Nadia Marascio, Angela Quirino, Giorgio Settimo Barreca, Luisa Galati, Chiara Costa, Vincenzo Pisani, Maria Mazzitelli, Giovanni Matera, Maria Carla Liberto, Alfredo Focà, Carlo Torti

Clin Mol Hepatol. 2019;25(1):30-36. Published online January 23, 2019

DOI: https://doi.org/10.3350/cmh.2018.0061

View: 8887 Download: 158 Web of Science: 16 Crossref: 18

Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals

Soon Young Ko, Won Hyeok Choe

Clin Mol Hepatol. 2018;24(4):351-357. Published online March 16, 2018

DOI: https://doi.org/10.3350/cmh.2017.0063

View: 11019 Download: 355 Web of Science: 4 Crossref: 1

2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C

The Korean Association for the Study of the Liver (KASL)

Clin Mol Hepatol. 2018;24(3):169-229. Published online August 10, 2018

DOI: https://doi.org/10.3350/cmh.2018.1004

View: 16596 Download: 233 Web of Science: 21 Crossref: 28

Original Article

Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals

Alessio Strazzulla, Giuseppe Coppolino, Giorgio Settimo Barreca, Innocenza Gentile, Laura Rivoli, Maria Concetta Postorino, Maria Mazzitelli, Giuseppe Greco, Chiara Costa, Vincenzo Pisani, Nadia Marascio, Mariadelina Simeoni, Alfredo Focà, Giorgio Fuiano, Daniela Foti, Elio Gulletta, Carlo Torti

Clin Mol Hepatol. 2018;24(2):151-162. Published online April 24, 2018

DOI: https://doi.org/10.3350/cmh.2017.0059

View: 7731 Download: 122 Web of Science: 15 Crossref: 13

Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study

Kwang Il Seo, Byung Chul Yun, Weiquan James Li, Sang Uk Lee, Byung Hoon Han, Eun Taek Park

Clin Mol Hepatol. 2017;23(1):74-79. Published online March 3, 2017

DOI: https://doi.org/10.3350/cmh.2016.0052

View: 8502 Download: 152 Web of Science: 3 Crossref: 4

Review

Management of direct antiviral agent failures

María Buti, Rafael Esteban

Clin Mol Hepatol. 2016;22(4):432-438. Published online December 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0107

View: 12397 Download: 366 Web of Science: 31 Crossref: 29

The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy

Ioannis Varbobitis, George V. Papatheodoridis

Clin Mol Hepatol. 2016;22(3):319-326. Published online September 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0045

View: 14854 Download: 414 Web of Science: 76 Crossref: 77

Original Article

Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection

Hee Chul Nam, Hae Lim Lee, Hyun Yang, Myeong Jun Song

Clin Mol Hepatol. 2016;22(2):259-266. Published online June 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0020

View: 10556 Download: 170 Web of Science: 8 Crossref: 7

Review

Chronic hepatitis B in pregnancy: unique challenges and opportunities

Kumaresan Yogeswaran, Scott K. Fung

Clin Mol Hepatol. 2011;17(1):1-8. Published online March 21, 2011

DOI: https://doi.org/10.3350/kjhep.2011.17.1.1

View: 9239 Download: 71 Crossref: 16

Correspondence

Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage

Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming- Lung Yu

Received February 28, 2025 Accepted March 1, 2025

DOI: https://doi.org/10.3350/cmh.2025.0235 [Accepted]

View: 630 Download: 23

1 |

Viewed By 12462	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7607	Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Viewed By 7052	MAFLD: How is it different from NAFLD?
Viewed By 5653	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5518	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 366	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 348	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 232	MAFLD: How is it different from NAFLD?
Cited By 122	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 116	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search